To include your compound in the COVID-19 Resource Center, submit it here.

FDA issues CRL for PTC's Translarna in DMD

PTC Therapeutics Inc. (NASDAQ:PTCT) said FDA issued a complete response letter for Translarna ataluren to treat nonsense mutations

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE